Clinical trial
Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive…
NCT00151060 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00151060 |
|---|---|
| Title | Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate |
| Official title | Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Patients With Hormonally Responsive Adenocarcinoma of the Prostate |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Estramustine, Etoposide, Paclitaxel |
| Enrollment | 28 |
| Start date | Dec 1, 1998 |
| Primary completion | Nov 1, 2004 |
| Completion | Jun 1, 2006 |
| First posted | Sep 8, 2005 |
| Last update posted | Jan 21, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: